Prevention and treatment of neutropenia in routine clinical practice. How to improve the quality of cancer care and reduce treatment costs?
https://doi.org/10.17650/1994-4098-2023-19-2-69-81
Abstract
Neutropenia is a common complication during anti-cancer therapy. Risk factors for febrile neutropenia, its diagnostic criteria, and methods of its prevention and treatment have been well described. In this article, we demonstrated the need to assess cost effectiveness of primary prevention of complications associated with polychemotherapy and treatment of neutropenia, as well as the need to analyze their incidence. Individual risk assessment of febrile neutropenia, implementation of the antimicrobial drug registry, and administration of pegylated granulocyte colony-stimulating factor reduced the incidence of neutropenia, its duration, and the number of antimicrobial drugs used. This, in turn, improved the quality of healthcare and optimized the use of hospital resources.
About the Author
G. A. Gromova
Republican Oncology Dispensary
Russian Federation
Competing Interests:
Russian Federation
Galina A. Gromova.
5 Lososinskoe Shosse, Petrozavodsk 185016, Republic of Karelia
Competing Interests:
None
References
1. Sapkota B., Shrestha R., Chapagai S. et al. Validation of risk of chemotherapy-induced neutropenia: experience from Oncology Hospital of Nepal. Cancer Manag Res 2020;12:3751–8. DOI: 10.2147/CMAR.S243916
2. Ostroumova O.D., Kochetkov A.I., Pavleeva E.E., Kravchenko E.V. Drug-induced neutropenia and agranulocytosis. Bezopastnost i risk farmakoterapii = Safety and risk of pharmacotherapy 2020;8(3):109–22. (In Russ.). DOI: 10.30895/2312-7821-2020-8-3-109-122
3. Sakaeva D.D., Borisov K.E., Bulavina I.S. et al. Practical Recommendations for the Diagnosis and Treatment of Febrile Neutropenia. Malignant Tumors. Practice Guidelines RUSSCO #3s2, 2022 (Vol. 12). Pp. 55–63. (In Russ.)
4. Accompanying Therapy in Oncology: A practical guide. Eds.: S.Yu. Moorcraft, D.L.Yu. Lee, D. Cunningham. Transl. from English ed. by A.D. Kaprin. M.: GEOTAR-Media, 2019. 440 p. (In Russ.)
5. Protocol for the Prevention of Febrile Neutropenia with Granulocyte Colony-Stimulating Factors. 5th edn., rev. and add., ed. by RAS Academician M.I. Davydov, 2021. Available at: https:// rassc.org/ru/recommendations. (In Russ.)
6. State Register of Medicines. Available at: https://grls.rosminzdrav.ru/Default.aspx. (In Russ.)
7. Guidelines for Chemotherapy of Tumor Diseases. Ed. by N.I. Perevodchikova, V.A. Gorbunova. 4th edn., exp. and add. M.: Prakticheskaya meditsina, 2018. 688 p. (In Russ.)
8. Whyte S., Cooper K.L., Stevenson M.D. et al. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom. Value Health 2011;14(4):465–74. DOI: 10.1016/j.jval.2010.10.037
Review
For citations:
Gromova G.A. Prevention and treatment of neutropenia in routine clinical practice. How to improve the quality of cancer care and reduce treatment costs? Tumors of female reproductive system. 2023;19(2):69-81. (In Russ.) https://doi.org/10.17650/1994-4098-2023-19-2-69-81
Views:
324
Email this article 